WEDNESDAY, Nov. 9 (HealthDay News) -- For the first time,
"epigenetic" therapy has shown promise in patients with solid
tumors, in this case non-small cell lung cancers.
Of 45 patients in a trial of this experimental treatment, two
had a complete response to therapy, one had a partial response and
one is still alive more than four years after starting therapy.
"It's not a home run, but this trial has opened the door for further research into epigenetic therapy," said Dr. Stephen Baylin, co-author of the study appearing online Nov. 9 and in the December issue of Cancer Discovery.
Other experts were both hopeful and cautious.
"The exciting part of this study is that they're using therapies that have really never worked in solid tumors, and this is one of the first studies to show that these types of therapies may work in solid tumors, and more specifically in lung cancer," said Dr. Benjamin Levy, director of thoracic medical oncology at Beth Israel Medical Center in New York City. "But until we get this validated in larger studies, it's unclear where this type of therapy in terms of altering epigenetic regulation is going to have a place in lung cancer."
"You have to view this as extremely preliminary. It is a small study with what one could almost argue are anecdotal-type findings," said Dr. Edward Kim, chief of head and neck medical oncology at MD Anderson Cancer Center in Houston. "There's not a lot I could apply to my patients, though the results are intriguing."
Some 80 percent of lung cancers are non-small cell lung cancers,
which have few effective treatments and, consequently, a dire
Epigenetic therapy involves targeting the proteins wrapped
around DNA, which regulate changes in actual gene expression.
Unlike genetic mutations, epigenetic abnormalities can be reversed,
This phase 1/2 trial involved 45 patients with metastatic
non-small cell lung cancer who had tried and failed multiple other
One of the drugs used in the study, azacitidine, had been tested
on different cancers decades ago but was deemed too toxic to use.
It's now approved in much lower doses for patients with
myelodysplastic syndrome, which can be a precursor to leukemia.
These researchers also used low doses of azacitidine, combined
with a newer drug, etinostat. Each drug targets a different
With this combination, patients lived an average of 6.4 months,
which is about two months longer than what otherwise would have
been expected, said Levy.
Two patients saw "a virtually complete response," said Baylin,
who is a professor of oncology and deputy director of the Kimmel
Cancer Center at Johns Hopkins University in Baltimore. One lived
for three years after therapy before dying of a different type of
lung tumor. The other is still alive three years after joining the
trial and "his original disease metastasis to his liver has not
After completing the epigenetic therapy, four patients went on
to respond to other therapies. "This has set up the possibility
that we're priming patients so that subsequent therapies work
better," Baylin said, cautioning that this is not yet proven.
Importantly, side effects were "milder than typical
chemotherapy," Baylin said. "No patient had to come off of the
trial because of toxicity."
The researchers were also able to identify biomarkers that may
be able to predict which patients will respond well to this
"This doesn't work in a majority of patients, but there is a small subset that really derive exceptional benefits from this approach," said Rudin. The challenge now is to identify these patients, he added.
Although the study suggested an association between the therapy
and increased survival, it does not prove a cause-and-effect.
The U.S. National Cancer Institute has more on
non-small-cell lung cancer.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.